VCA Stocks

Trellis Bioscience, Inc., a privately held biotechnology company, announced today that it has raised $10 million in a Series B Preferred Stock venture capital financing In addition to applying CellSpot(TM) to the discovery and manufacturing needs of partners, Trellis is developing a pipeline of native human antibodies for the treatment of infectious disease and oncology